PCSK9 Inhibition at the Front Lines of CAD Prevention and Treatment

Program Medium

Internet-based program


Estimated Time to Complete Educational Activity

1.5 hours


Course Overview

This CME Clinical Excellence Summit is directed at the following clinical specialists and  providers: atherosclerosis, thrombosis, lipid, and cardiology specialists  and related healthcare providers who manage patients with patients with persistent or inadequately controlled hypercholesterolemia.


Release Date

September 30, 2018


Expiration Date

September 30, 2020


Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period September 2018  through September 2020 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 4 segments totaling 1.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.



Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.


Grantor Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Postgraduate Institute for Medicine and CMEducation Resources, LLC. ‘The Postgraduate Institute for Medicine  is accredited by the ACCME to provide continuing medical education for physician.


Credit Designation Statement

The Postgraduate Institute for Medicine  designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Policy on Faculty & Provider Disclosure

Postgraduate Institute for Medicine  requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to Postgraduate Institute for Medicine  policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.



Program Faculty and Disclosure

Professor Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI,FESC
Program Chair

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center 
Professor of Medicine 
Harvard Medical School 
Boston, Massachusetts 

Contracted Research: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, The Medicines Company


Professor Philippe Gabriel Steg, MD
Professor of Cardiology 
Université Paris – Diderot, Sorbonne-Paris Cité
Professor, National Heart and Lung Institute
Imperial College, London, UK
Director, Coronary Care Unit
Hôpital Bichat | Paris, France

Research grants: Bayer, Merck, Sanofi, Servier
Speaker or consultant: Amarin, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Servier

Professor J. Wouter Jukema, MD, PhD, FESC, FACC
Professor of Cardiology
Netherlands Heart Foundation
Chairman, Leiden Vascular Medicine 
Leiden University Medical Center (LUMC) 
Leiden, Netherlands


 Research grants and/or speaker fees: Amgen, Astra-Zeneca, Biotronik, Daiichi Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Sanofi Aventis, The Medicine Company, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Interuniversity Cardiology Institute of the Netherlands, and the European Community Framework KP7 Progra


Educational Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate and interpret the evidence supporting the safety and outcome-linked benefits of lowering LDL-C as a primary strategy to decrease cardiovascular risk for a wide range of patients with persistent or inadequately controlled hypercholesterolemia
  • Determine when, in which patients, and with what practical dosing and monitoring strategies newer lipid-lowering agents, including those based on PCSK9 inhibition, should be used and their role in the treatment of patients with persistently elevated LDL-C
  • Outline design, results, and outcomes of landmark clinical trials addressing the safety and efficacy of non-statin therapiesfor medical management of high risk patients with of elevated LDL-C in, including those patients with a prior recent ACS event and/or advanced ASCVD accompanied by poorly controlled LDL-C levels
  • Screen for suboptimal LDL-C levels and identifying high risk groups with risk factors and/or a previous history of CAD/ASHD—including individuals with recent ACS, familial hypercholesterolemia, history of ASHD, and/or diabetes—who are appropriate candidates for PCSK9 inhibition
  • Apply evidenced-based, scientifically substantiated international (ESC/EAS) guideline recommendations and clinical decision tree pathways and international consensus guidelines and recommendations for treating patients with LDL-C levels that require lowering to optimize clinical outcomes
  • Explain the pharmacoeconomic impact and clinical implications of managed care-based barriers placed on subgroups of patients using LDL-lowering therapies for persistent uncontrolled LDL-C elevations as well as long-term implications of inadequately managed, recurrent ACS;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.


Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

·        We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.

·        For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

·        We may use the Information to send you information about other CME activities that CMEducation Resources is offering.

·        If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.You should check this privacy policy periodically to see whether we have made any changes.